China is one of the countries with high incidence of liver cancer. With the continuous development of liver surgical diagnosis and treatment technology, the clinical pathological diagnosis of liver cancer in China has been rapidly improved, and it has obvious advantages in the number and type of liver cancer pathological specimens. In order to formulate individualized treatment plan and improve the long-term curative effect of liver cancer, new requirements are also put forward for the contents of pathological report of liver cancer. Although medical units have accumulated thousands or even tens of thousands of diagnostic experiences, on the whole, the development of pathological diagnosis of liver cancer in China is still unbalanced, and the contents and formats of pathological reports vary greatly, which can't fully meet the needs of clinical individualization and fine treatment. Therefore, the "Expert Consensus Seminar on Standardized Pathological Diagnosis Protocol of Primary Liver Cancer" jointly organized by the Liver Cancer Professional Committee of China Anti-Cancer Association, the Clinical Oncology Collaborative Professional Committee of China Anti-Cancer Association, the Hepatology Group of Hepatology Society of Chinese Medical Association and the National Hepatobiliary Tumor and Transplantation Pathology Collaborative Group was held in Shanghai on January 17, 2010. At the meeting, the main leaders of relevant professional societies and participating experts and scholars had a heated discussion on the standardized pathological diagnosis of primary liver cancer, and extensively exchanged the experience and practices accumulated by their units in the diagnosis and research practice of immunopathology and molecular pathology of liver tumors. From the perspective of the actual needs of clinical diagnosis and treatment, they put forward many constructive opinions and suggestions on the standardized pathological diagnosis of liver cancer, and introduced the practices of some foreign hospitals in the pathological diagnosis of liver tumors, striving to formulate a consensus scheme for pathological diagnosis of liver tumors that can better meet the clinical needs in China. On this basis, a preliminary consensus draft is put forward, and the consultation is further expanded, and the consensus scheme is repeatedly revised. Finally, the consensus scheme is formed for reference in practical work, and will be continuously revised and improved.
